Publications by authors named "A A Yunis"
Background: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.
Objectives: To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.
Article Synopsis
- - The study investigated the effects of two heart preservation methods—ice-cold storage (ICS) and the Paragonix SherpaPak CTS—on ischemia reperfusion injury (IRI) following heart transplantation, as ischemic times have increased since the 2018 allocation system change.
- - Analysis of biopsies from 90 heart transplant recipients showed similar IRI rates between the two methods, but the CTS group had a significant reduction in coagulative myocyte necrosis (CMN) from weeks 1 to 4, and both methods showed reductions by week 8.
- - Despite longer ischemic times with CTS, the study found no significant differences in rejection rates or survival between the groups, suggesting that CTS is a viable option
Objectives: To evaluate the clinical implications of adjunctive molecular gene expression analysis (MMDx ) of biopsy specimens in heart transplant (HT ) recipients with suspected rejection.
Introduction: Histopathological evaluation remains the standard method for rejection diagnosis in HT. However, the wide interobserver variability combined with a relatively common incidence of "biopsy-negative" rejection has raised concerns about the likelihood of false-negative results.
Wild-type transthyretin amyloidosis (ATTRwt) results in an infiltrative cardiomyopathy often culminating in symptomatic heart failure. The use of cardiopulmonary exercise testing (CPET) in determining outcomes in ATTRwt cardiac amyloidosis is unknown. Given the emergence of novel therapies to treat transthyretin amyloidosis, we sought to investigate the utility of CPET on outcomes in patients with ATTRwt cardiomyopathy.
View Article and Find Full Text PDFBackground: Heart failure (HF) involves myocardial fibrosis and dysregulated angiogenesis.
Objective: We explored whether biomarkers of fibrosis and angiogenesis correlate with HF severity.
Methods: Biomarkers of fibrosis [procollagen types I and III (PIP and P3NP), carboxyterminal-telopeptide of type I collagen (ICTP), matrix metalloproteases (MMP2 and MMP9), tissue inhibitor of MMP1 (TIMP1)]; and angiogenesis [placental growth factor (PGF), vascular endothelial growth factor (VEGF), soluble Fms-like tyrosine kinase-1 (sFlt1)] were measured in 52 HF patients and 19 controls.